Dermatol Online J. 2026 May 8;32(2). doi: 10.25251/4dmwat50.
ABSTRACT
BACKGROUND: Apalutamide is an androgen receptor antagonist used to treat patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) or metastatic castration-sensitive prostate cancer (mCSPC). One of the most frequent adverse events associated with apalutamide is skin rash, particularly in Japanese patients. However, preventive skin care may reduce the frequency of apalutamide-induced skin rashes.
OBJECTIVE: We sought to compare the cumulative incidence of skin rashes in patients on apalutamide therapy with and without preventive skin care.
METHODS: This retrospective, real-world study included 27 patients in the control group (those who were not administered skin care) and 38 patients in the skin care group (those who were administered preventative skin care).
RESULTS: After a median follow-up of 7 months, grade 3 apalutamide-induced skin rashes occurred in 8.1% (3/37) of patients in the skin care group and 53.6% (15/28) of patients in the control group. Based on Gray’s test, the difference in incidence between groups was statistically significant (P = .002).
CONCLUSION: Preventive skin moisturization may reduce apalutamide-induced adverse skin events in patients with mCSPC or nmCRPC. Incorporating routine skin care may help patients experience the full efficacy of apalutamide while maintaining a good quality of life.
PMID:42522476 | DOI:10.25251/4dmwat50
